Bergabunglah dengan Buletin Kami
Bergabunglah dengan daftar pelanggan kami untuk mendapatkan artikel terkini, update dan penawaran khusus langsung di kotak masuk Anda
Company initiates US launch following ANDA approval for bioequivalent to Brivia...
Value caps under the scheme have also been reduced by 50 per cent wherever appl...
Biocon Group Chairperson recognised for contributions to biomedical science and...
This marks a key development in the potential approval of adrabetadex, which cou...
These facilities will integrate advanced manufacturing technologies and AI for s...
Product is therapeutically equivalent to Jublia; company holds 234 USFDA ANDA a...
Institute spinout Miraqules MedSolutions secures regulatory clearance for techn...
GlobalData highlights that the FDA’s review of Moderna’s mRNA-1010, with a 05 A...
Only two monoclonal antibodies approved in both markets with no small molecules...
CDSCO approval enables planned March 2026 launch targeting Type 2 diabetes mana...
The approval was granted by the US Food and Drug Administration (FDA) and follow...
Following positive CHMP opinion, Lupin to commercialise RanluspecTM in EU throu...
The submission targets adult patients with oestrogen receptor (ER)-positive, hum...
Laboratory balance requirements across global pharmacopeias have been significa...
351(k) Biologics License Application for DRL_AB IV infusion targets rheumatoid ...
Multi-year contract to commence supplies within 4–5 months, execution planned t...
